Commentary · 8 Oct 2025
Review articlePublished 3 Mar 2017
From a "Eureka Insight" to Novel Concepts in Pharmaceutical Sciences: Role of Ca2+/cAMP Intracellular Signalling Interaction
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
It has been almost 4 years since we revealed the explanation for the enigma of the so-called “calcium paradox”. Our discovery of the involvement of Ca2+/cAMP signaling interaction in the regulation of neurotransmitter release, and neuroprotection, was clearly a serendipitous discovery. It has produced new avenues in the understanding of the cellular and molecular mechanisms involved in the pathogenesis of neurological and psychiatric disorders, such as Alzheimer´s disease. Interestingly, this discovery initiated decades ago when numerous clinical studies have reported that use of L-type Ca2+ channel blockers (CCBs) by hypertensive patients decreased arterial pressure, but produced typical symptoms of sympathetic hyperactivity, such as tachycardia and increment of catecholamine plasma levels. Despite these adverse effects of CCBs have been initially attributed to adjust reflex of arterial pressure, during almost four decades this enigmatic phenomenon (the so-called "calcium paradox") remained unclear. In 2013, through an ingenious experiment, we discovered that this phenomenon was resulting of increment of transmitter release from sympathetic neurons, and adrenal chromaffin cells, stimulated by CCBs due to its interference on the Ca2+/cAMP signaling interaction. In this way, our discovery of the role of Ca2+/cAMP intracellular signaling interaction in the neurotransmitter release, and neuronal death triggered by cytosolic Ca2+ overload, opened novel adventures for the development of new pharmacological strategies more effective for the treatment of neurological and psychiatric disorders resulting of neurotransmitter release deficit, and neuronal death. These novel concepts have been extensively documented in several cited international papers of our own authorship (Bergantin and Caricati-Neto), and in an international book.
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Annals of Clinical and Laboratory Research.
Mini review · 2 Oct 2025
Characteristics and Treatment of Juvenile Myasthenia Gravis
Commentary · 9 Jul 2025
Commentary on Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: Real-World Data from 134 Patients
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalAnnals of Clinical and Laboratory Research
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Leandro Bueno Bergantin”
- BylineArticles whose byline prints “Afonso Caricati-Neto”
